Sign in

Immunotherapy Advances

@imtadvances.bsky.social
339 followers 22 following 203 posts

#OpenAccess journal covering the translational pipeline for #immunotherapy 🎯Included in WoS, PubMed & Scopus

PostsRepliesMedia
Immunotherapy Advances @imtadvances.bsky.social · 30/09/2026
🧬 Open‑access study shows how spatial immune architecture and macrophage polarization shape immunotherapy responses in mismatch repair–deficient colorectal cancer, helping explain why metastatic lesions respond differently. 👉 vist.ly/5kesq #Immunotherapy
doi.org
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
AbstractIntroduction. Mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit variable clinical responses to immune checkpoint inhibitors (ICIs)
011
Immunotherapy Advances @imtadvances.bsky.social · 28/09/2026
Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders. Read here📄 bit.ly/4pw1rVL
011
Immunotherapy Advances @imtadvances.bsky.social · 25/09/2026
How Streptococcus pneumoniae interacts with innate immunity matters. New open‑access research shows neuraminidase A (NanA) shapes immune sensing and phagocytic clearance in microglia and macrophages, with implications for pneumococcal meningitis. vist.ly/5jtib
doi.org
Neuraminidase A controls pneumococcal recognition and fate: deficiency enhances immune sensing and intracellular survival, while treatment promotes phagocytic clearance.
Abstract. Streptococcus pneumoniae (pneumococcus) is a leading cause of bacterial meningitis worldwide and is associated with cerebrovascular complications
021
Immunotherapy Advances @imtadvances.bsky.social · 23/09/2026
Open‑access review explores how targeting monocyte dynamics could offer new therapeutic approaches for multiple sclerosis, with insights from experimental models highlighting monocyte plasticity and inflammation resolution. vist.ly/5jhn9
022
Immunotherapy Advances @imtadvances.bsky.social · 22/09/2026
New research shows that adding CD28 signalling motifs to the CD3ζ chain boosts IL‑2 production and expansion of TCR‑engineered T cells, without reducing cytotoxicity. A promising step toward stronger TCR therapies for solid tumours. Read here: vist.ly/5jcu9 #Immunotherapy #TCells
021
Immunotherapy Advances @imtadvances.bsky.social · 21/09/2026
🚀 Building on years of CAR‑T and TCR‑T innovation, this study showcases a sophisticated “all‑in‑one” engineered T‑cell approach for AML, combining antigen specificity, microenvironment responsiveness, bystander recruitment, and a safety switch in a single vector. Read more: vist.ly/5j9yx
Diagram of TCR signaling pathways with GM-CAR, CD3xCD33 BiTE, and tEGFR-cetuximab suicide switch.
032
Immunotherapy Advances @imtadvances.bsky.social · 21/09/2026
New open‑access paper outlines how the UK Vaccine Innovation Pathway is accelerating cancer vaccine trials across the NHS, boosting recruitment, streamlining delivery, and supporting equitable access. vist.ly/5j8hb
000
Immunotherapy Advances @imtadvances.bsky.social · 18/09/2026
This study maps the spatial + immune landscape of metastatic dMMR colorectal cancer, revealing why some lesions respond to immunotherapy while others resist. Macrophage polarization and spatial immune architecture emerge as key drivers of outcome. 🔗 vist.ly/5ixaq
021
Reposted by Immunotherapy Advances
British Society for Immunology @britsocimm.bsky.social · 17/09/2026
It's #PeerReviewWeek and we want to recognise the valuable contributions of peer reviewers for their vital role in ensuring science can be shared in a timely way. Thank you to all who generously give their time and expertise to improve the quality of research published in our journals and beyond!
Thank you to our reviewers poster with immunology journal covers.
124
Immunotherapy Advances @imtadvances.bsky.social · 15/09/2026
Submissions are still open for our CD40 turns 40 Special Collection, exploring four decades of CD40 biology and its impact on immunotherapy across cancer, autoimmunity, and more 🧬 Learn more about submitting here: vist.ly/5ihwy #Immunology #Immunotherapy
academic.oup.com
Call for Papers
Immunotherapy Advances publishes scientifically rigorous open access research relating to manipulations of the immune system for the benefit of human and a
031
Immunotherapy Advances @imtadvances.bsky.social · 15/09/2026
This review explores the bottom-up development of LGR5-targeting immunotherapeutics, showing how a highly specific α‑LGR5 antibody can be adapted into multiple modalities 📖 Read more: vist.ly/5ihju #Immunotherapy #CancerResearch #CARTcells #PrecisionMedicine #OpenAccess
Wnt pathway illustration with modulation by RSPO showing gene expression changes.
021
Reposted by Immunotherapy Advances
British Society for Immunology @britsocimm.bsky.social · 14/09/2026
We're at #BSICambridge26 today! if you're attending, do come and say hello and ask us about our membership, journals and professional development opportunities.
043
Immunotherapy Advances @imtadvances.bsky.social · 27/08/2026
Check out this open‑access paper outlines how the UK Vaccine Innovation Pathway is accelerating cancer vaccine trials across the NHS, boosting recruitment, streamlining delivery, and supporting equitable access. vist.ly/5gcug
021
Immunotherapy Advances @imtadvances.bsky.social · 14/08/2026
🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it. Read: vist.ly/5est6
011
Immunotherapy Advances @imtadvances.bsky.social · 11/08/2026
🔬 Can we better monitor responses to JAK inhibitors? This study presents two flow cytometry assays with potential as biomarkers for treatment monitoring and personalized care. 📄 vist.ly/5ecdb
doi.org
Development and evaluation of two whole-blood flow cytometry protocols for monitoring patients treated with JAK inhibitors
AbstractIntroduction. The clinical efficacy of Janus kinase inhibitors (JAKinibs) is highly variable and their safety profiles are poorly understood.Method
011
Immunotherapy Advances @imtadvances.bsky.social · 07/08/2026
🧬 Regulatory B cells may be helping clear cell renal cell carcinoma evade the immune system. Researchers found that increased Breg signatures were linked to poorer outcomes, a more immunosuppressive tumour environment, and reduced responses to immunotherapy. 🔗 vist.ly/5dyg7
Regulatory B cells promote the immunosuppressive microenvironment and progression of clear cell renal cell carcinoma
011
Immunotherapy Advances @imtadvances.bsky.social · 06/08/2026
A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs. Read the open access article: vist.ly/5dtf7
Infographic on Ig20Gly study for Japanese patients with primary immunodeficiency.
011
Immunotherapy Advances @imtadvances.bsky.social · 05/08/2026
🧬 Regulatory B cells (Bregs) are emerging as key regulators of immune homeostasis and disease. A timely review on their biology and therapeutic potential. 📖 vist.ly/5dp74 #Immunology #Immunotherapy #BCells
doi.org
Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting
Abstract. The field of immunology is increasingly intersecting with molecular biology, metabolic biology, and neurobiology (Zhu et al, A neuroimmune circui
011
Immunotherapy Advances @imtadvances.bsky.social · 31/07/2026
PI3K hyperactivation is a key driver of APDS and related immune disorders. This review explores disease mechanisms, diagnostic strategies, targeted treatments, and remaining clinical challenges. vist.ly/5d68s #IEI #Immunology #PrecisionMedicine
doi.org
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives
Abstract. The phosphoinositide-3-kinase (PI3K) pathway function is crucial to the normal development, differentiation, and function of immune cells includi
011
Immunotherapy Advances @imtadvances.bsky.social · 31/07/2026
Regulatory B cells (Bregs) help maintain immune tolerance, but their roles in autoimmune disease are remarkably diverse. This review explores how Breg phenotypes and functions vary across conditions and what that means for future therapies. 🔗 vist.ly/5d4vc
doi.org
Heterogeneity of regulatory B cells in autoimmune diseases: implications for immune equilibrium and therapeutic strategies
Abstract. Regulatory B cells (Bregs) play a crucial role in maintaining immune tolerance and preventing autoimmune diseases. However, in autoimmune conditi
021
Immunotherapy Advances @imtadvances.bsky.social · 30/07/2026
Radiolabeled nanobodies are emerging as powerful tools for cancer imaging, offering rapid target detection and high target-to-background contrast. Explore their growing role in supporting cancer diagnosis and immunotherapy monitoring. 🔗 vist.ly/5cyc9 #CancerResearch
Diagram of cancer cells, T cells, and myeloid cells showing immune checkpoints.
031
Immunotherapy Advances @imtadvances.bsky.social · 29/07/2026
🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it. Read: vist.ly/5cvmh
011
Immunotherapy Advances @imtadvances.bsky.social · 28/07/2026
🧬 New research suggests G-CSF supportive care may come with an immunological trade-off: improved neutrophil recovery but reduced checkpoint blockade efficacy in immunotherapy-responsive pancreatic cancer models. vist.ly/5cr86 #PancreaticCancer #Immunotherapy #Oncology #CancerResearch
doi.org
Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer
AbstractIntroduction. Growth factors, including granulocyte colony-stimulating factor (G-CSF; pegfilgrastim, filgrastim), are used for prophylaxis or treat
011
Immunotherapy Advances @imtadvances.bsky.social · 23/07/2026
🔬 Radiolabeled nanobodies are emerging as powerful tools for cancer immunotherapy, enabling non-invasive imaging of tumours, immune checkpoints, and immune cells to support patient selection and treatment monitoring. 📖 vist.ly/5c72w
Diagram showing TAM, myeloid cells, cancer cells, and T cells with labeled molecules.
011
Immunotherapy Advances @imtadvances.bsky.social · 22/07/2026
🧬 CAR-T cells and TCR-T cells don't regulate cytokine production in the same way. Patel and colleagues show that while co-stimulatory receptors are needed to sustain late cytokine production in TCR-T cells, this regulation is largely lost in 2nd-generation CAR-T cells. 📖 vist.ly/5c3w8
Graph comparing cytokine production of TCR/1st Gen and 2nd Gen CAR over time.
011
Immunotherapy Advances @imtadvances.bsky.social · 20/07/2026
🎗️ Cancer stem cells may be a key missing piece in understanding immunotherapy resistance. This comprehensive review examines how CSCs interact with the tumour microenvironment and discusses emerging strategies to target stemness-driven therapeutic failure. 📖 vist.ly/5btf3
Diagram of signaling pathways related to cancer stem cells with text boxes and arrows.
011
Immunotherapy Advances @imtadvances.bsky.social · 17/07/2026
🚀 New in Immunotherapy Advances! Margherita Boieri et al. from Zelluna ASA report promising preclinical data on MAGE‑A4–specific TCR‑NK cells, showing potent, safe activity against solid tumors. Read the open access article: vist.ly/5bip5 #Immunotherapy #CellTherapy
Infographic showing ZH-MA4-1a cancer therapy process with diagrams and annotations.
021
Immunotherapy Advances @imtadvances.bsky.social · 15/07/2026
Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders. Read here📄vist.ly/5ba67
011
Immunotherapy Advances @imtadvances.bsky.social · 14/07/2026
NLRC5 is more than an MHC-I regulator. Shukla et al. show that tumour-intrinsic NLRC5 promotes CD8⁺ T-cell and NK-cell infiltration, rewires antigen-processing pathways, and drives tumour control, highlighting its potential as a target to enhance antitumour immunity. 🧬 vist.ly/5b6jx
Illustration of tumor cells with text on immune response and MHC-I presentation.
011
Immunotherapy Advances @imtadvances.bsky.social · 10/07/2026
Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy. This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening. 📄 vist.ly/5asfu
Diagram of B cell lineage and immune response in tumor microenvironment.
011
Immunotherapy Advances @imtadvances.bsky.social · 08/07/2026
🔬 New pediatric PID data: fSCIG 10% maintained stable IgG levels across ages 2–16 years, with comparable PK profiles and support for individualized dosing. A step toward reducing treatment burden while preserving effective IgG replacement. 💉 vist.ly/5agfe
doi.org
Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease
AbstractIntroduction. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is a unique and effective treatment for primary immunodeficienc
011
Immunotherapy Advances @imtadvances.bsky.social · 07/07/2026
A phase 3 study by Kanegane et al. reports that 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or every 2 weeks maintained stable IgG levels with a favourable safety profile in Japanese patients with PIDs. Read the open access article: vist.ly/5adn2
Infographic on Ig20Gly study for Japanese patients with primary immunodeficiency.
011
Immunotherapy Advances @imtadvances.bsky.social · 03/07/2026
Metabolic dysregulation plays a key role in Behçet’s disease. Elevated glucose & TAG levels drive Th1 differentiation, CD8⁺ T cell activation and B cell antibody production, contributing to immune dysfunction. Read the study: vist.ly/59xtz
Infographic showing immune cell disruptions in Behçet's disease.
121
Immunotherapy Advances @imtadvances.bsky.social · 02/07/2026
CD137 aptamer–shRNA chimeras show promise for targeting intratumoral Tregs. This approach downregulates key genes like EzH2 & Nrp1 in CD137⁺ Tregs and malignant cells, offering a potential new route for tumour immunotherapy. 🔗 vist.ly/59urf
Charts showing effects of CD137 treatment with statistics.
011
Immunotherapy Advances @imtadvances.bsky.social · 01/07/2026
A new study protocol describes a controlled human lung immune challenge using inhaled Resiquimod (R848) to investigate antiviral immune responses and airway inflammation, helping to advance respiratory research and novel therapy development. 🔗 vist.ly/59qts
Infographic outlining lung immune challenge model objectives, timeline, and outcomes.
011
Immunotherapy Advances @imtadvances.bsky.social · 30/06/2026
🔬 A high-affinity ImmTAC® can redirect T cells to kill PRAME+ tumour cells, even at low antigen levels. A promising approach for targeting hard-to-reach cancer antigens. 📖 vist.ly/59jfd
doi.org
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer–testis antigen PRAME
AbstractBackground. PRAME (Preferentially expressed Antigen in Melanoma) is a cancer–testis antigen expressed in several tumor indications, representing an
011
Immunotherapy Advances @imtadvances.bsky.social · 26/06/2026
PRAME-targeted ImmTAC® efficiently redirected T cells to kill tumour cells, with activity enhanced by anti-PD-1 therapy, highlighting its potential across multiple cancer types. 📖 vist.ly/595zb #Immunotherapy #Oncology #CancerResearch
doi.org
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer–testis antigen PRAME
AbstractBackground. PRAME (Preferentially expressed Antigen in Melanoma) is a cancer–testis antigen expressed in several tumor indications, representing an
000
Immunotherapy Advances @imtadvances.bsky.social · 25/06/2026
🔬 MAGE-A4-specific TCR-NK cells showed potent preclinical activity against solid tumors, combining targeted and innate tumor killing in a promising off-the-shelf cell therapy. 🔗 vist.ly/593g8
doi.org
Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors
Abstract. T cell (Tc) receptor (TCR)-based cell therapies have shown clinical efficacy across many cancer types and represent an attractive strategy for ta
011
Immunotherapy Advances @imtadvances.bsky.social · 24/06/2026
M2 macrophages may help protect against asthma by promoting IL-10⁺ regulatory B cells. In a mouse model, macrophage depletion worsened asthma symptoms, while findings suggest M2 macrophages support IL-10⁺ B-cell activity via TGF-β and oxidative phosphorylation pathways. 📖 vist.ly/58wxa
doi.org
M2 macrophages promote IL-10+B-cell production and alleviate asthma in mice
AbstractIntroduction. B cells have a central regulatory role in various diseases. While macrophages are found in the disease microenvironment and interact
000
Immunotherapy Advances @imtadvances.bsky.social · 24/06/2026
🔬 M2 macrophages can boost IL-10–producing B cells, helping reduce inflammation and ease asthma symptoms in mouse models. Highlights a potential new avenue for modulating immune responses in asthma. 📖 vist.ly/58v4w #Immunology #Asthma
doi.org
M2 macrophages promote IL-10+B-cell production and alleviate asthma in mice
AbstractIntroduction. B cells have a central regulatory role in various diseases. While macrophages are found in the disease microenvironment and interact
000
Immunotherapy Advances @imtadvances.bsky.social · 19/06/2026
📍 We're at #OCION2026 today in Oxford! Stop by the Immunotherapy Advances booth to meet our Journals Manager, Laura Franklin, and chat about publishing your latest immunology and immuno-oncology research. We're actively welcoming submissions! 🧬✨
011
Reposted by Immunotherapy Advances
Oxford Academic @academic.oup.com · 17/06/2026
Discover the benefits available when peer reviewing for the @britsocimm.bsky.social journals, including a chance to work with immunology experts to advance research. 🔗 oxford.ly/4fWq6kZ #ImmunoSky | @ceijournal.bsky.social | @imtadvances.bsky.social | @discovimmunol.bsky.social
Call for reviewers: become an ad hoc reviewer for the BSI journals
075
Immunotherapy Advances @imtadvances.bsky.social · 18/06/2026
🔬 Monocytes play a key role in MS, balancing inflammation and tissue repair. Shifting from pro-inflammatory to repair-associated subsets could offer new therapeutic approaches. 📖 vist.ly/588k5 #Immunology #MultipleSclerosis
000
Immunotherapy Advances @imtadvances.bsky.social · 18/06/2026
🔬 Monocytes play a key role in MS, balancing inflammation and tissue repair. Shifting from pro-inflammatory to repair-associated subsets could offer new therapeutic approaches. 📖 vist.ly/587dc #Immunology #MultipleSclerosis
Abstract. Monocytes are central to the innate immune system’s response to infection or injury. In murine, these cells are classified into distinct subsets:
011
Immunotherapy Advances @imtadvances.bsky.social · 17/06/2026
CAR-T cells lose the temporal regulation of cytokine production seen in TCR-T cells, producing sustained high cytokine levels without external co-stimulation, which may underpin both their potency and toxicity. 🔬 vist.ly/584c5 #Immunology
doi.org
Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells
Abstract. CD8+ T cells contribute to immune responses by producing cytokines when their T-cell receptors (TCRs) recognise peptide antigens on major-histoco
000
Immunotherapy Advances @imtadvances.bsky.social · 11/06/2026
Phase 3 data show 20% subcutaneous Ig (Ig20Gly) given weekly or every 2 weeks maintains protective IgG levels (>8 g/L) with a favourable safety profile in Japanese patients with PIDs. Flexible dosing with promising clinical impact. vist.ly/57csr #Immunology
doi.org
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study
Abstract. This phase 3, open-label, multidose study (NCT04346108) evaluated the pharmacokinetics, safety, tolerability, and efficacy of immunoglobulin subc
011
Immunotherapy Advances @imtadvances.bsky.social · 10/06/2026
Study shows comparable cellular immunogenicity in chronic plaque psoriasis patients receiving continuous Humira® or repeated switching with biosimilar AVT02, supporting interchangeability findings. vist.ly/57a58 #Psoriasis #Biosimilars #Immunology
doi.org
Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02
Summary. Immunogenicity against biologic medicines is ubiquitous, and it is traditionally measured by the final humoral response. However, the onset of a s
011
Immunotherapy Advances @imtadvances.bsky.social · 09/06/2026
🔬 Immune sensing vs clearance isn’t always aligned. New work shows loss of neuraminidase A boosts detection of S. pneumoniae but enables intracellular survival, while restoring it improves clearance. Points to NanA as a potential therapeutic target. 📖 vist.ly/573pm
doi.org
Neuraminidase A controls pneumococcal recognition and fate: deficiency enhances immune sensing and intracellular survival, while treatment promotes phagocytic clearance.
Abstract. Streptococcus pneumoniae (pneumococcus) is a leading cause of bacterial meningitis worldwide and is associated with cerebrovascular complications
011
Immunotherapy Advances @imtadvances.bsky.social · 05/06/2026
Tracking engineered T cells after infusion is crucial. This study shows a rapid whole-blood assay can assess TCR T cell function in vivo, with cytokine responses reflecting dose in HBV-related liver cancer. 🔗 vist.ly/56rb4 #Immunotherapy #TCells #Immunology
doi.org
A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells
AbstractIntroduction. The clinical efficacy of chimeric antigen and T cell receptor (TCR) T cell immunotherapies is attributed to their ability to prolifer
011
Immunotherapy Advances @imtadvances.bsky.social · 02/06/2026
🔬 Regulatory B cells are key to immune balance, but their role in autoimmune disease is highly variable. This highlights the need for more personalised approaches to treatment. 📖 vist.ly/56c84
Abstract. Regulatory B cells (Bregs) play a crucial role in maintaining immune tolerance and preventing autoimmune diseases. However, in autoimmune conditi
011